UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: A new class of antibacterial agents

Current Medicinal Chemistry

Volumn 19, Issue 13, 2012, Pages 2038-2050

  Zhang, J ^a   Zhang, L ^a   Li, X ^b   Xu, W ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biosynthesis; FtsH; Gram negative bacteria; Lipid A; LpxC; LpxC Inhibitors; MDR; Structure

Indexed keywords

ANTIINFECTIVE AGENT; HYDROXAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; URP 3 O (3 HYDROXYMYRISTOYL) N ACETYLGLUCOSAMINE DEACETYLASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BORDETELLA BRONCHISEPTICA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; CATALYST; CHEMICAL REACTION; DEACETYLATION; DRUG DESIGN; DRUG STRUCTURE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MICROCYSTIS AERUGINOSA; NONHUMAN; SALMONELLA TYPHIMURIUM; VIBRIO CHOLERAE;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860535850     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800167374     Document Type: Article

References (64)

1. Levy, S. B. Anticbiotic resistence-the problem intensifies. Adv. Drug Deliv. Riv., 2005, 57(10), 1446-1450.
2. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med., 2004, 10(12), 122-129.
3. Wright M. O. Multi-resistant gram-negative organisms in Maryland: a statewide survey of resistant Acinetobacter baumannii. Am. J. Infect Control, 2005, 33(7), 419-421.
4. Paterson, D. L. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Med., 2006, 119(6), S20-8.
5. Shannon, B. F.; Eric, D. B. New screens and targets in antibacterial drug discovery. Curr. Opin. Microbiol, 2009, 12(5), 497-504.
6. Walsh, C. where will new antibiotics come from? Nat. Rev. Microbiol, 2003, 1(1), 65-70.
7. Projan, S. J. New (and not so new) antibacterial targets-from where and when will the novel drugs come? Curr. Opin. Pharm., 2002, 2(5), 513-522.
8. Projan, S. J.; Youngman, P. J. Antimicrobials: New solutions badly needed. Curr. Opin. Microbiol, 2002, 5(5), 463-465.
9. Raetz, C. R. Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction. Journal of bacteriology, 1993, 175(18), 5745-5743.
10. Vuorio, R.; Vaara M. The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrobial Agents and Chemotherapy, 1992, 36(4), 826-829.
11. Wyckoff, T. J.; Raetz, C. R.; Jackman, J. E. Antibacterial and antiinflammatory agents that target endotoxin. Trends in Microbiology, 1998, 6(4), 154-159. (Pubitemid 28202433)
12. Whittington, D. A.; Rusche, K. M.; Shin, H.; Fierke, C. A.; Christianson, D. W. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. PNAS, 2003, 100(14), 8146-8150. (Pubitemid 36842513)
13. Raetz, C. R.; Whitfield, C. Lipopolysaccharide endotxins. Annual review of biochemistry, 2002, 71(1), 635-700.
14. Nikaido, H.; Vaara, M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev., 1985, 49(1), 1-32. (Pubitemid 15134118)
15. Vaara, M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy, 1993, 37(2), 354-356. (Pubitemid 23046584)
16. Anderson, M. S.; Robertson, A. D.; Macher, I.; Raetz, C. R. Biosynthesis of lipid A in Escherichia coli: Identification of UDP-3-O-(R-3-hydroxymyristoyl) -R-D-glucosamine as a precursor of UDP-N2-O3-bis-(R-3-hydroxymyristoyl)-R-D- glucosamine. Biochemistry,1988, 27(6), 1908-1917.
17. Anderson, M. S.; Bull, H. G.; Galloway, S. M.; Kelly, T. M.; Mohan, S.; Radika, K.; Raetz, C. R. UDP-Nacetylglucosamine acyltransferase of Escherichia coli: The first step of endotoxin biosynthesis is thermodynamically unfavorable, J. Biol. Chem., 1993, 268(26), 19858-19865. (Pubitemid 23270781)
18. White, R. J.; Margolis, P. S.; Trias, J.; Yuan, Z. Targeting metalloenzymes: A strategy that works. Curr. Opin. Pharmacol, 2003, 3(5), 502-507. (Pubitemid 37221130)
19. Stover, C. K.; Pham, X. Q.; Erwin, A. L.; Mizoguchi, S. D.; Warrener, P.; Hickey, M. J.; Brinkman, F. S.; Hufnagle, W. O.; Kowalik, D. J.; Lagrou, M.; Garber, R. L.; Goltry, L.; Tolentino, E.; Westbrock-Wadman, S.; Yuan, Y.; Brody, L. L.; Coulter, S. N.; Folger, K. R.; Kas, A.; Larbig, K.; Lim, R.; Smith, K.; Spencer, D.; Wong, G. K.; Wu, Z.; Paulsen, I. T.; Reizer, J.; Saier, M. H.; Hancock, R. E.; Lory, S.; Olson, M. V. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature, 2000, 406(6799), 959-964.
20. Blattner, F. R.; Plunkett, G.; Bloch, C. A.; Perna, N. T.; Burland, V.; Riley, M.; Collado-Vides, J,; Glasner, J. D.; Rode, C. K.; Mayhew, G. F.; Gregor, J.; Davis, N.W.; Kirkpatrick, H. A.; Goeden, M. A.; Rose, D. J.; Mau, B.; Shao Y. The complete genome sequence of Escherichia coli K-12. Science, 1997, 277(5331),1453-1474.
21. Coggins, B. E.; Li, X. C.; McClerren, A. L.; Hindsqual, O.; Raetz, C. R.; Zhou, P. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nature Structural Biology, 2003, 10(8), 645-651. (Pubitemid 36944718)
22. Coggins, B. E.; McClerren, A. L.; Jiang, L.; Li, X. C.; Rudolph, J.; Hindsgual, O.; Raetz, C. R.; Zhou, P. Refined solution structure of the LpxCTU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design. Biochemistry, 2005, 44(4), 1114-1126. (Pubitemid 40208991)
23. Brab, A. W.; Jiang, L.; Raetz, C. R.; Zhou, P. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. PNAS, 2007, 104(47), 18433-18438. (Pubitemid 350210714)
24. Mochalkin, I.; Knafels, J. D.; Lightle, S. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor. Protein Science, 2008, 17(3), 450-457. (Pubitemid 351281545)
25. Gennadios, H.; Christianson, D. W. Binding of uridine 5′-diphosphate in the "basic patch" of the zinc deacetylase LpxC and implications for substrate binding. Biochemistry, 2006, 45(51), 15216-15223. (Pubitemid 46032448)
26. Brab, A. W.; Zou, P. Mechanism and inhibition of LpxC: an essential zincdependent deacetylase of bacterial Lipid A synthesis. Curr. Pharm. Bio., 2008, 9: 9-15.
27. Buetow, L.; Dawson, A.; Hunter W. N. The nucleotide-binding site of Aquifex aeolicus LpxC. Structural Biology And Crystallization Communications, 2006, 62(11), 1082-1086. (Pubitemid 44684143)
28. Hernick, M.; Gennadios, H. A.; Whittington, D. A.; Rusche, K. M.; Christianson, D. W.; Fierke, C. A. UDP-3-O-((R)-3-hydroxymyristoyl)- Nacetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism. Journal of Biological Chemistry, 2005, 280(17), 16969-16978. (Pubitemid 41389158)
29. McClerren, A. L.; Zhou, P.; Guan, Z. Q.; Raetz, C. R.; Rudolph, J. Kinetic analysis of the znc-dependent deacetylase in the Lipid A biosynthetic pathway. Biochemistry, 2005, 44(4), 1106-1113. (Pubitemid 40208990)
30. Hernick, M.; Fierke, C. A. Zinc hydrolases: the mechanisms of zincdependent deacetylases. Arch. Biochem. Biophys., 2005, 433(1), 71-84. (Pubitemid 39586584)
31. Robinet, J. J.; Gauld, J. M. DFT investigation on the mechanism of the deacetylation reaction catalyzed by LpxC. J. Phys. Chem., 2008, 112(11), 3462-3469.
32. Gennadios, H. A.; Whittington, D. A.; Li, X. C.; Fierke, C. A.; Christianson, D. W. Mechanistic inferences from the binding of ligands to LpxC, a metaldependent deacetylase. Biochemistry, 2006, 45(26), 7940-7948. (Pubitemid 43993217)
33. Ogura, T.; Inoue, K.; Tatsuta, T.; Suzaki, T.; Karata, K.; Young, K.; Su, L. H.; Fierke, C. A.; Jackman, J. E.; Raetz, C. R.; Coleman, J.; Tomoyasu, T.; Matsuzawa, H. Balanced biosynthesis of major membrane components through regulated degradation of the committed enzyme of lipid A biosynthesis by the AAA protease FtsH (HflB) in Escherichia coli. Mol. Microbiol., 1999, 31(3), 833-844. (Pubitemid 29057286)
34. Jayasekera, M. M.; Foltin, S. K.; Olson, E. R.; Holler, T. P. Escherichia coli requires the protease activity of FtsH for growth. Arch. Biochem. Biophys., 2000, 380(1), 103-107. (Pubitemid 30616776)
35. Susan, G. Proteolysis in bacteria regulatory circuits. Annu. Rev. Cell Dev. Biol., 2003, 19, 565-587.
36. Ito, K.; Akiyama, Y. Celluar functions, mechanism of action, and regulation of FtsH protease. Annu. Rev. Microbio., 2005, 59, 211-231. (Pubitemid 41507430)
37. Führer, F.; Langklotz, S.; Narberhaus, F. The C-terminal end of LpxC is required for degradation by the FtsH protease. Molecular Microbiology, 2006, 59(3), 1025-1036.
38. Führer, F.; Müller, A.; Baumann, H.; Langklotz S.; Kutscher, B.; Narberhaus, F. Sequence and length recognition of the C-terminal turnover element of LpxC: a soluble substrate of the membrane-bound FtsH protease. J. Mol. Biol., 2007, 372(2), 485-496. (Pubitemid 47267962)
39. Katz, C.; Ron, E. Z. Dual role of FtsH in regulating lipopolysaccharide biosynthesis in Escherichia coli. Journal of Bacteriology, 2008, 190(21), 7117-7122.
40. Langklotz, S.; Schakermann, M.;Narberhaus, F. Control of lipopolysaccharide biosynthesis by FtsH-mediated proteolysis of LpxC is conserved in Enterobacteria but not in all Gram-negative bacteria. Journal of Bacteriology, 2011, 193(5), 1090-1097.
41. Onishi, H. R.; Pelak, B. A.; Gerckens, L. S.; Silver, L. L.; Kahan, F. M.; Chen, M. H.; Patchett, A. A.; Galloway, S. M.; Hyland S. A.; Anderson, M. S.; Raetz, C. R. Antibacterial agents that inhibit Lipid A biosynthesis. Science, 1996, 274(5289), 980-982. (Pubitemid 26398419)
42. Chen, M. H.; Steiner, M. G.; de Laszlo, S. E.; Patchett, A. A.; Anderson, M. S.; Hyland S. A.; Onishi, H. R.; Silver, L. L.; Raetz, C. R. Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis. Bioorganic & medicinal chemistry Letters, 1999, 9(3), 313-318. (Pubitemid 29084485)
43. Jackman, J. E.; Fierke, C. A.; Tumey, L. N.; Pirrung, M. C.; Uchiyama, T.; Tahir, S. H.; Hindsqual, O.; Raetz, C. R. Antibacterial agents that target lipid A biosynthesis in Gram-negative bacteria. Journal of Biological Chemistry, 2000, 275(15), 11002-11009.
44. Mdluli, K. E.; Witte, P. R.; Kline, T.; Brab, A. W.; Erwin A. L.; Mansfield, B. E.; McClerren, A. L.; Pirrung, M. C.; Tumey, L. N.; Warrener, P.; Raetz, C. R.; Stover, C. K. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50(6), 2178-2184. (Pubitemid 43807540)
45. Kline, T.; Anderson, N. H.; Harwood, E. A.; Bowman, J.; Malanda, A.; Endsley, S.; Erwin, A. L.; Doyle, M.; Fong, S.; Harris, A. L.; Mendelsohn, B.; Mdluli, K.; Raetz, C. R.; Stover, C. K.; Witte, P. R.; Yabannavar, A.; Zhu, S. G. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J. Med. Chem., 2002, 45(14), 3112-3129. (Pubitemid 34721533)
46. Pirrung, M. C.; Tumey, L. N.; Raetz, C. R.; Jackman, J. E.; Snehalatha, K.; McClerren, A. L.; Fierke, C. A.; Gantt, S. L.; Rusche, K. M. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups. J. Med. Chem., 2002, 45(19), 4359-4370. (Pubitemid 35025582)
47. Pirrung, M. C.; Tumey, L. N.; McClerren, A. L.; Raetz, C. R. High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties. J. Am. Chem. Soc., 2003, 125(6), 1575-1586. (Pubitemid 36206239)
48. Anderson, N. H.; Bowman, J.; Erwin, A.; Harwood, E.; Kline T.; Mdluli, K.; Simon, N. G.; Pfister, K. B.; Shawar, R.; Wagman, A.; Asha, Y. Antibacterial agents. WO2004062601. 2004.
49. McClerren, A. L.; Endsly, S.; Bowman, J. L.; Adersen, N. H.; Guan, Z. Q.; Rudolph, J.; Raetz, C. R. A slow, tight-binding inhibitor of the zincdependent deacetylase LpxC of Lipid A biosynthesis with antibiotic activity comparable to Ciprofloxacin. Biochemistry, 2005, 44(50), 16574-16583. (Pubitemid 41832039)
50. Barb, A. W.; McClerren, A. L.; Snehelatha K.; Reynolds, C. M.; Zhou, P.; Raetz, C. R. Inhibition of Lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry, 2007, 46(12), 3793-3802. (Pubitemid 46493479)
51. Cole, K. E.; Gattis, S. G.; Angell, H. D.; Fierke, C. A.; Christianson, D. W. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090. Biochemistry, 2011, 50(2), 258-265.
52. Lee, C. J.; Liang, X. F.; Chen X.; Zeng, D. N.; Joo, S. H.; Chung, H. S.; Barb, A. W.; Swanson, S. M.; Nicholas, R. A.; Li, Y. X.; Toone, E. J.; Raetz, C. R.; Zhou, P. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. Chemistry & Biology, 2010, 18(1), 38-47.
53. Liang, X. F.; Lee, C. J.; Chen X.; Chung, H. S.; Zeng, D. N.; Raetz, C. R.; Li, Y. X.; Zhou, P.; Toone, E. J. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold. Bioorg. Med. Chem., 2011, 19(2), 852-860.
54. Mansoon, U. F.; Vitharana, D.; Reddy, P. A.; Daubaras, D. L.; Mcnicholas, P.; Orth, P.; Black, T.; Siddiqui, M. A. Design and synthesis of potent Gramnegative specific LpxC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(4), 1155-1161.
55. Cheng, X. C.; Wang, Q; Fang, H.; Xu W. F. Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr. Med. Chem., 2008, 15(4), 368-373. (Pubitemid 351266942)
56. Clements, J. M.; Coiqanard, F.; Johnson, I.; Chandler, S.; Palan, S.; Waller, A.; Wijkmans, J.; Hunter, M. G. Antibacterial activities and characterization of novel intibitors of LpxC. Antimicrob. Agents. Chemother., 2002, 46(9), 1793-1799. (Pubitemid 34535199)
57. Tu, G. G.; Xu, W. F.; Huang, H. M.; Li, S. H. Progress in the Development of Matrix Metalloproteinase Inhibitors. Curr. Med. Chem., 2008, 15(4), 1388-1395. (Pubitemid 351997789)
58. Zhang, X. P.; Xu, W. F. Aminopeptidase N (APN/CD13) as a target for anticancer agent design. Curr. Med. Chem., 2008, 15(27), 2850-2865.
59. Hanson, J. E.; Kaplan, A. P.; Bartlett, P. A. Phosphonate analogues of carboxypeptidase A substrates are potent transition-state analogue inhibitors. Biochemistry, 1989, 28(15), 6294-6305. (Pubitemid 19202018)
60. Holden, H. M.; Tronrud, D. E.; Monzingo, A. F.; Weaver, L. H.; Matthews, B. W. Slow-and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. Biochemistry, 1987, 26(26), 8542-8553.
61. Mansoor, U. F.; Reddy, P.; Adulla, P.; Siddiqui, M. A. Hydantoin derivatives useful as antibacterial agents. WO 2008/027466 A1.
62. Cuny, G. D. A new class of UDP-3-O-(R-3-hydroxymyristol)- Nacetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gramnegative infections: PCT application WO 2008027466. Expert Opin. Ther. Patents, 2009, 19(6), 893-899.
63. Shin, H.; Gennadios, H. A.; Whittington, D. A.; Christianson, D. W. Amphipathic benzoic acid derivatives: Synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC. Bioorg. Med. Chem., 2007, 15(7), 2617-2623. (Pubitemid 46367709)
64. Brab, A. W.; Leavy, T. M.; Robins, L. I.; Guan, Z. Q.; Six, D. A.; Zhou, P.; Bertozzi, C. R.; Raetz, C. R. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC. Biochemistry, 2009, 48(14), 3068-3077.